0.38Open0.38Pre Close0 Volume100 Open Interest17.50Strike Price0.00Turnover248.02%IV69.64%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.38Extrinsic Value100Contract SizeAmericanOptions Type0.1806Delta0.0560Gamma27.74Leverage Ratio-0.0523Theta0.0005Rho5.01Eff Leverage0.0050Vega
Y-mAbs Therapeutics Stock Discussion
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
Y-mAbs Therapeutics (NASDAQ: YMAB)presented preclinical data and trial progress for its CD38-SADA platform at the 2024 ASH Annual Meeting. The preclinical data demonstrated selective binding and anti-tumor efficacy of CD38-SADA when used with Lutetium 177-DOTA in treating Non-Hodgkin Lymphoma (NHL).
The company also...
No comment yet